Infusion centers are experiencing rapid growth, but reimbursement complexity is rising just as fast. High-cost drugs, strict payer rules, and frequent prior authorization requirements make collections more challenging each year. In 2026, infusion providers must take a proactive approach to infusion center accounts receivable and denial management to protect cash flow. Emerging trends are reshaping how infusion centers handle AR, appeals, and payer relationships. Today, the typical causes of increasing denials and bad debt include:
- discrepancies between authorization and infusion product classification,
- denials for medical necessity when utilizing continuing medications,
- coding mod errors, and
- late follow-up on high-dollar and unpaid billings
Whenever these processes are ignored as mandated, they tend to build quickly into large AR backlogs.
That being said, here are the top trends to optimize AR management and denial prevention for your infusion center in 2026.Â
Trend 1: Separating AR by Drug Classification
2026 will see a major trend in infusion centers’ separating AR by drug classification of service provided, rather than treating all infusion claims equally. As a result, leading infusion agencies will start tracking the following:
- A separate AR account of high-dollar biologics vs. routine infusions
- Denials by drug category and/or provider
- The length of time accounts receivable have been outstanding for therapeutic drugs
This type of tracking will assist staff in focusing on claims impacting the financial needs of the organization.
Trend 2: Improved Relationship between Authorization and Billing
The continued high volume of denials that occur for infusion therapy services is because of the failure of the billed service to be recorded properly, as authorized by a payer. Currently, each practice is working to maximize the level of integration between authorizations and billing into daily workflows. Best practices currently include:
- Confirm through verification procedures the CPT/HCPCS codes, units billed, and date of service billed as matching authorization.
- Whenever there is a modification to the course of treatment, a new authorization must be submitted to the system.
- At the time of billing/submittal, double-check to ensure the authorization has been uploaded/obtained from the system.
- A close alignment of authorizations and billing will yield fewer preventable denials as well as a more efficient workflow.
Trend 3: Centralized Appeals Management
There is an increasing trend of creating centralized and more structured processes for appeals across infusion organizations. A centralized appeal management process may include:
- Templates for the most common infusion denial codes.
- Documentation checklists for narcotic drugs and specialty drugs.
- Single-point appeal tracking system for documenting both the deadline and the outcome of an appeal.
- Centralized structures through standardization of appeal processes can lead to increased overturn rates and reduced administrative burden on staff.
Trend 4: Outsourcing Specialized AR/Denial Management Services for Your Infusion Center
With infusion volumes continuing to grow in complexity, more infusion centers are choosing to partner with accounts receivable and denial management companies that offer tailored solutions to this specialty to boost their collections. Specialized partners like RCM Workshop can offer:
- Â Dedicated account receivable follow-up teams
- Â Infusion-specific denial management expertise
- Â Timeliness of appeals to payers and follow-up
- Â Scalable support for growth or staffing gaps
By outsourcing, the infusion center can remain focused on providing high-quality clinical care while protecting revenue. By 2026, all infusion centers should consider proactive AR and denial management as strategic priorities in their organization, whether done internally or by utilizing an experienced infusion center accounts receivable and denial management service. This will enable infusion centers to receive timely reimbursement, reduce write-offs, and drive sustainable financial growth.
